Literature DB >> 18003673

Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence.

David Preiss, Naveed Sattar.   

Abstract

" 'Diagnosis' of metabolic syndrome by any current criteria is not needed and adds little to clinical practice. Attention and resources should be focused on the major modifiable risk factors and more should be done to engender sustainable lifestyle changes in all with vascular disease."

Entities:  

Mesh：

Year:  2007        PMID： 18003673      PMCID： PMC2095767          DOI： 10.1136/hrt.2007.130849

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  29 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Screening for type 2 diabetes and impaired glucose metabolism: the Australian experience.

Authors:  Stephen Colagiuri; Zafirul Hussain; Paul Zimmet; Adrian Cameron; Jonathan Shaw
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

3.  Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.

Authors:  D J Freeman; J Norrie; N Sattar; R D Neely; S M Cobbe; I Ford; C Isles; A R Lorimer; P W Macfarlane; J H McKillop; C J Packard; J Shepherd; A Gaw
Journal:  Circulation       Date:  2001-01-23       Impact factor: 29.690

Review 4.  Banting lecture 1988. Role of insulin resistance in human disease.

Authors:  G M Reaven
Journal:  Diabetes       Date:  1988-12       Impact factor: 9.461

5.  Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease?

Authors:  Michael P Stern; Ken Williams; Clicerio González-Villalpando; Kelly J Hunt; Steven M Haffner
Journal:  Diabetes Care       Date:  2004-11       Impact factor: 19.112

6.  Within- and between-subject variation in commonly measured anthropometric and biochemical variables.

Authors:  A Widjaja; R J Morris; J C Levy; K N Frayn; S E Manley; R C Turner
Journal:  Clin Chem       Date:  1999-04       Impact factor: 8.327

7.  HbA1c screening for undiagnosed diabetes in New Zealand.

Authors:  Tracy L Ellison; Robert Elliott; Simon A Moyes
Journal:  Diabetes Metab Res Rev       Date:  2005 Jan-Feb       Impact factor: 4.876

8.  Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.

Authors:  Naveed Sattar; Allan Gaw; Olga Scherbakova; Ian Ford; Denis St J O'Reilly; Steven M Haffner; Chris Isles; Peter W Macfarlane; Chris J Packard; Stuart M Cobbe; James Shepherd
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study.

Authors:  Julia Hippisley-Cox; Carol Coupland; Yana Vinogradova; John Robson; Margaret May; Peter Brindle
Journal:  BMJ       Date:  2007-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.